​

Funding Round

Series B - Nuvalent

Series B - Nuvalent

Investment Firm

Overview

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.

Announced Date

May 11, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Bain Capital Life Sciences

Bain Capital Life Sciences

Bain Capital Life Sciences is a early_stage_venture and private_equity and venture firm.

Participant Investors

10

Investor Name
Participant InvestorBain Capital Life Sciences
Participant InvestorAvoro Capital Advisors
Participant InvestorDeerfield
Participant InvestorWellington Management
Participant InvestorFidelity

Round Details and Background

Nuvalent raised $135000000 on 2021-05-11 in Series B

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 27, 2021
Series A - Nuvalent
1-50.0M
May 11, 2021
Series B - Nuvalent
12-135.0M
Oct 31, 2022
Post-IPO Equity - Nuvalent
-264.5M
Oct 16, 2023
Post-IPO Equity - Nuvalent
-300.0M

Recent Activity

There is no recent news or activity for this profile.